Mackenzie Financial
FATE icon

Mackenzie Financial’s Fate Therapeutics FATE Stock Holding History

Mackenzie Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,456
Closed -$261K – 1439
2021
Q4 		$261K Sell
4,456
-240
-5% -$13.6K ﹤0.01% 1211
2021
Q3 		$278K Buy
4,696
+1,914
+69% +$150K ﹤0.01% 1167
2021
Q2 		$241K Buy
+2,782
New +$224K ﹤0.01% 1117

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Mackenzie Financial's FATE Position: Q1 2022 in Review

Mackenzie Financial sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 4,456 shares — an estimated $261K sold.

Mackenzie Financial first reported a position in FATE in Q2 2021 and held it in 3 quarters. The position peaked at $278K in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Mackenzie Financial reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Mackenzie Financial sold 4,456 Fate Therapeutics shares in Q1 2022, an estimated $261K.
  • Mackenzie Financial first reported a position in Fate Therapeutics in Q2 2021 and held it in 3 quarters.
  • Mackenzie Financial's Fate Therapeutics position peaked at $278K in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Mackenzie Financial's 13F filing for Q1 2022, filed 13 May 2022.